Research for new drugs for elimination of onchocerciasis in Africa.
Research for new drugs for elimination of onchocerciasis in Africa.
复制标题
DOI：
10.1016/j.ijpddr.2016.04.002
复制
发表时间：
2016-12
影响因子：
4
通讯作者：
Kuesel, Annette C.
中科院分区：
文献类型：
--
作者：
Kuesel, Annette C.
盘尾丝虫病是由盘尾丝虫病引起的一种寄生虫病媒传播疾病。99%以上有感染风险的人口生活在非洲。西非于1974年开始控制盘尾丝虫病媒，后来辅以伊维菌素大规模药物管理，1995年在其他非洲流行国家每年使用伊维菌素进行社区指导治疗。这大大降低了感染流行率。再加上塞内加尔和马里疫源年度CDTI消除盘尾丝虫病的概念证明，这已导致到2020年在选定的非洲国家消除盘尾丝虫病，到2025年在80%的非洲国家消除盘尾丝虫病。实现这些目标所面临的挑战包括：冲突推迟或中断控制规划的流行国家的数量、跨界疫源地、可能出现对伊维菌素易感性较低的寄生虫菌株，以及另一种寄生虫媒介传播疾病——路易病的共同流行，这些都减缓或阻止了CDTI的实施。其中一些挑战可以通过新药或对盘尾丝虫的效果比伊维菌素更高的药物组合来解决。本文综述了从新化合物的发现到它们获得大规模使用资格的途径，以及监管部门为开发治疗被忽视的热带病的药物提供的支持。综述了盘尾丝虫病新药或治疗方案在获得监管机构批准和大规模使用资格的道路上的研究现状。这项研究包括伊维菌素和阿苯达唑的新方案和组合，针对O. vervulus Wolbachia的抗生素，氟苯达唑，莫西丁素和emodepside以及新化合物的发现。消除盘尾丝虫病需要新药的挑战。人用药物从发现到鉴定的路径概述。为开发治疗被忽视疾病的药物提供监管支持和激励措施。新给药方案、药物组合及抗扭转弧菌新药的发展。
Onchocerciasis is a parasitic, vector borne disease caused by the filarial nematode Onchocerca volvulus. More than 99% of the population at risk of infection live in Africa. Onchocerciasis control was initiated in West Africa in 1974 with vector control, later complemented by ivermectin mass drug administration and in the other African endemic countries in 1995 with annual community directed treatment with ivermectin (CDTI.) This has significantly reduced infection prevalence. Together with proof-of-concept for onchocerciasis elimination with annual CDTI from foci in Senegal and Mali, this has resulted in targeting onchocerciasis elimination in selected African countries by 2020 and in 80% of African countries by 2025. The challenges for meeting these targets include the number of endemic countries where conflict has delayed or interrupted control programmes, cross-border foci, potential emergence of parasite strains with low susceptibility to ivermectin and co-endemicity of loiasis, another parasitic vector borne disease, which slows down or prohibits CDTI implementation. Some of these challenges could be addressed with new drugs or drug combinations with a higher effect on Onchocerca volvulus than ivermectin. This paper reviews the path from discovery of new compounds to their qualification for large scale use and the support regulatory authorities provide for development of drugs for neglected tropical diseases. The status of research for new drugs or treatment regimens for onchocerciasis along the path to regulatory approval and qualification for large scale use is reviewed. This research includes new regimens and combinations of ivermectin and albendazole, antibiotics targeting the O. volvulus endosymbiont Wolbachia, flubendazole, moxidectin and emodepside and discovery of new compounds. Challenges for onchocerciasis elimination requiring new drugs. Summary of path from discovery to qualification of drugs for human use. Regulatory support and incentives for development of drugs for neglected diseases. Development of new dose regimens, drug combinations and new drugs against O. volvulus.
登录
查看更多内容
DOI：
10.1080/00034983.1980.11687330
发表时间：
1980-01-01
影响因子：
--
作者：
AWADZI, K
通讯作者：
AWADZI, K
影响因子：
2.7
作者：
Ali, MMM;Mukhtar, MM;Mackenzie, CD
通讯作者：
Mackenzie, CD
影响因子：
--
作者：
Awadzi, K;Attah, SK;Edwards, G
通讯作者：
Edwards, G
影响因子：
8.1
作者：
Ajayi, Ikeoluwapo O.;Jegede, Ayodele S.;Sommerfeld, Johannes
通讯作者：
Sommerfeld, Johannes
影响因子：
--
作者：
Awadzi, K;Edwards, G;Quartey, BT
通讯作者：
Quartey, BT